Switching from levodopa to the long-acting dopamine D2/D3 agonist piribedil reduces the expression of dyskinesia while maintaining effective motor activity in MPTP-treated primates

Clinical Neuropharmacology

Volumn 29, Issue 3, 2006, Pages 112-125

  Smith, Lance A ^a   Jackson, Michael J ^a   Johnston, Louisa ^a   Kuoppamaki, Mikko ^a,c   Rose, Sarah ^a   Al Barghouthy, Ghassan ^a   Del Signore, Susanna ^b   Jenner, Peter ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b SATAKUNTA CENTRAL HOSPITAL   (Finland)

^c IRIS Institut de Recherches Internationales Servier   (France)

Author keywords

Dyskinesia; Levodopa; MPTP treated primate; Parkinson disease; Piribedil

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; CARBIDOPA; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; LEVODOPA; PIRIBEDIL; DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; DOPAMINE RECEPTOR STIMULATING AGENT;

ANALYTIC METHOD; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG EFFICACY; DRUG SUBSTITUTION; DYSKINESIA; FEMALE; MALE; MARMOSET; MOTOR ACTIVITY; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; PRIMATE; PRIORITY JOURNAL; ANIMAL; DRUG EFFECT; DRUG POTENTIATION; INTOXICATION; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; CALLITHRIX; DOPAMINE AGONISTS; DYSKINESIA, DRUG-INDUCED; FEMALE; LEVODOPA; MALE; MOTOR ACTIVITY; MPTP POISONING; PIRIBEDIL; RECEPTORS, DOPAMINE D2; RECEPTORS, DOPAMINE D3;

EID: 33746417219     PISSN: 03625664     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.WNF.0000220818.71231.DF     Document Type: Article

References (65)

1. Marsden CD, Parkes JD. "On-off" effects in patients with Parkinson's disease on chronic levodopa therapy. Lancet 1976;1:292-296.
2. Fahn S. The spectrum of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):S2-S11.
3. Nutt JG. Long-term levodopa therapy: challenges to our understanding and for the care of people with Parkinson's disease. Exp Neurol 2003;184:9-13.
4. Rascol O, Payoux P, Ory F, et al. Limitations of current Parkinson's disease therapy. Ann Neurol 2003;53(suppl 3):S3-S15.
5. Olanow CW, Agid Y, Mizuno Y, et al. Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 2004;19(9):997-1005.
6. Brotchie JM, Lee J, Venderova K. Levodopa-induced dyskinesia in Parkinson's disease. J Neural Transm 2005;112:359-391.
7. Olanow W, Schapira AHV, Rascol O. Continuous dopamine-receptor stimulation in early Parkinson's disease. Neuroscience 2000;23(suppl):S117-S126.
8. Olanow W, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(11 suppl 5):S1-S88.
9. Cristina S, Zangaglia R, Mancini F, et al. High-dose ropinirole in advanced Parkinson's disease with severe dyskinesias. Clin Neuropharmacol 2003;26(3):146-150.
10. Inzelberg R, Schechtman E, Nisipeanu P. Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence based comparison. Drugs Aging 2003;20(11):847-855.
11. Blanchet PJ, Calon F, Martel JC, et al. Continuous administration decreases and pulsatile administration increases behavioural sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 1995;272:854-859.
12. Maratos EC, Jackson MJ, Pearce RK, et al. Antiparkinsonian activity and dyskinesia risk of ropinirole and Levodopa combination therapy in drug naive MPTP-lesioned common marmosets. Mov Disord 2001;16:631-641.
13. Smith LA, Tel BC, Jackson MJ, et al. Repeated administration of piribedil induces less dyskinesia than levodopa in MPTP-treated common marmosets: a biochemical and behavioural investigation. Mov Disord 2002;17(5):887-901.
14. Bélanger N, Grégoire L, Hadj Tahar AH, et al. Chronic treatment with small doses of cabergoline prevents dopa-induced dyskinesias in parkinsonian monkeys. Mov Disord 2003;18(12):1436-1441.
15. Grace AA. The tonic/phasic model of dopamine system regulation and its implications for understanding alcohol and psychostimulant craving. Addiction 2000;95(suppl 2):S119-S128.
16. Olanow CW, Obeso JA. Preventing levodopa-induced dyskinesias. Ann Neurol 2000;47(4 suppl 1):S176-176. [discussion, S176-S168].
17. Floresco SB, West AR, Ash B, et al. Afferent modulation of dopamine neuron firing differently regulates tonic and phasic dopamine transmission. Nat Neurosci 2003;6(9):968-973.
18. Obeso JA, Rodriguez-Oroz MC, Rodrigues M, et al. Pathophysiology of levodopa-induced dyskinesias in PD: problems with the current model. Ann Neurol 2000;47(suppl 1):S32-S43.
19. Jenner P. Avoidance of dyskinesia: preclinical evidence for continuous dopaminergic stimulation. Neurology 2004;62(suppl 1):S47-S55.
20. Mouradian MM, Heuser IJ, Baronti F, et al. Modification of central dopaminergic mechanisms by continuous levodopa therapy for advanced Parkinson's disease. Ann Neurol 1990;27:18-23.
21. Shuah LA, Bennett JP. Suppression of dyskinesias in advanced Parkinson's disease. I. Continuous intravenous levodopa shifts dose response for production of dyskinesias but not for relief of parkinsonism in patients with advanced Parkinson's disease. Neurology 1993;43:1545-1550.
22. Colzi A, Turner K, Lees AJ. Continuous subcutaneous waking day apomorphine in the long-term treatment of levodopa induced interdose dyskinesias in Parkinson's disease. J Neurol Neurosurg Psychiatry 1998;64:573-576.
23. Syed N, Murphy J, Zimmerman T, et al. Ten years' experience with enteral levodopa infusion for motor fluctuations in Parkinson's disease. Mov Disord 1998;13:336-338.
24. Sharma JC, Macnamara L, Hasoon M, et al. Diagnostic and therapeutic value of apomorphine in parkinsonian patients. Int J Clin Pract 2004;58(11):1028- 1032.
25. Bibbiani F, Costantini LC, Patel R, et al. Continuous dopaminergic stimulation reduces risk of motor complications in parkinsonian primates. Exp Neurol 2005;192:73-78.
26. Nyholm D, Nilsson RA, Dizdar N, et al. Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. Neurology 2005;64(2):216-223.
27. Nutt JG. Clinical pharmacology of levodopa-induced dyskinesia. Ann Neurol 2000;47(suppl 1):S160-S166.
28. Rascol O, Arnulf I, Peyro-Saint PH, et al. Idazoxan, an alpha-2 antagonist, and L-dopa-induced dyskinesias in patients with Parkinson's disease. Mov Disord 2001;16(4):708-713.
29. Hadj Tahar AH, Grégoire L, Bangassoro E, et al. Sustained cabergoline treatment reverses levodopa-induced dyskinesias in parkinsonian monkeys. Clin Neuropharmacol 2000;23:195-202.
30. Bonucelli U, Colzi A, Del Dotto P. Pergolide in the treatment of patients with early and advanced Parkinson's disease. Clin Neuropharmacol 2002;1:1-10.
31. Tagaya H, Wetter TC, Winkelmann J, et al. Pergolide restores sleep maintenance but impairs sleep EEG synchronization in patients with restless legs syndrome. Sleep Med 2002;3:49-54.
32. Happe S, Trenkwalder C. Role of dopamine receptor agonists in the treatment of restless legs syndrome. CNS Drugs 2004;18(1):27-36.
33. Sarati S, Guiso G, Spinelli R, et al. Determination of piribedil and its basic metabolites in plasma by high-performance liquid chromatography. J Chromatogr 1991;563:323-332.
34. Allain H, Le Coz F, Del Signore S, et al. Piribedil plasma levels after chronic oral administration of Trivastal Retard 50 (150 mg/day) in parkinsonian patients. Parkinsonism Relat Disord 2001;7(suppl):S51.
35. Millan MJ, Maiofiss L, Cussac D, et al. Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes. J Pharmacol Exp Ther 2002;303(2):791-804.
36. Newman-Tancredi A, Cussac D, Audinot V, et al. Differential actions of antiparkinsonian agents at multiple classes of monoaminergic receptor. II. Agonist and antagonist properties at subtypes of dopamine D(2)-like receptor and alpha(1)/alpha(2)-adrenoceptor. J Pharmacol Exp Ther 2002;303(2):805-814.
37. Kwiecinski H, Fedorova N, Takats A, et al. A multicentre trial of piribedil as early adjunct treatment for Parkinson's disease: Piribedil International Study Group (PISG). Neurology 2002;58(suppl 3):A163.
38. Cesaro P, Aguilar M, Caldas AC, et al. The Parkinson-control study: a multicentre trial comparing piribedil (150 mg/day) to bromocriptine (25 mg/day) in early combination with L-dopa in Parkinson's disease. Eur J Neurol 2003;10(suppl 1):LB3.
39. Zeigler M, Castro-Caldas A, Del Signore S, et al. Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: a 6-month, randomised, placebo-controlled study. Mov Disord 2003;18(4):418-425.
40. Rascol O, Gershanik O, Blin O, et al. Piribedil efficacy in monotherapy (150-300 mg/day) in "de novo" parkinsonian patients: a 6-month planned intermediate analysis of the 2-year Parkinson regain study. Mov Disord 2004;19(suppl 9):603.
41. Rascol O, Castro-Caldas A, Dubois B, et al, on behalf of the PD-REGAIN study group. Early treatment of Parkinson's disease with the non-ergot dopamine agonist piribedil: 2-year results of the placebo-controlled REGAIN study. Mov Disord 2005: [late breaking abstract 10].
42. Smith L, De Salvia M, Jenner P, et al. An appraisal of the antiparkinsonian activity of piribedil in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine-treated common marmosets. Mov Disord 1996;11:125-135.
43. Smith LA, Jackson MJ, Bonhomme C, et al. Transdermal administration of piribedil reverses MPTP-induced motor deficits in the common marmoset. Clin Neuropharmacol 2000;23(3):133-142.
44. Smith LA, Jackson MJ, Hansard MJ, et al. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure. Mov Disord 2003;18(5):487-495.
45. Hansard MJ, Smith LA, Jackson MJ, et al. The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates. Mov Disord 2004;19(1):15-21.
46. Bédard PJ, Di Paolo T, Falardeau P, et al. Chronic treatment with levodopa, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding. Brain Res 1986;379:294-299.
47. Clarke CE, Sambrook MA, Mitchell IJ, et al. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). J Neurol Sci 1987;78:273-280.
48. Papa SM, Chase TN. Levodopa-induced dyskinesias improved by a glutamate antagonist in parkinsonian monkeys. Ann Neurol 1996;39:574-578.
49. Pearce RKB, Banerji T, Jenner P, et al. De novo administration of ropinirole and bromocriptine induces less dyskinesia that levodopa in the MPTP-treated marmoset. Mov Disord 1998;13:234-241.
50. Andringa G, Stoof JC, Cools AR. Sub-chronic administration of the dopamine D1 antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology 1999;146:328-334.
51. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 2000;47(suppl 1):S90-S104.
52. Calon F, Grondin R, Morissette M, et al. Molecular basis of levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):S70-S78.
53. Brotchie JM. The neural mechanisms underlying levodopa-induced dyskinesia in Parkinson's disease. Ann Neurol 2000;47(suppl 1):S105-S114.
54. Facca A, Sanchez-Ramos J. High-dose pergolide monotherapy in the treatment of severe levodopa-induced dyskinesias. Mov Disord 1996;11(3):327-329.
55. Rascol O. Medical treatment for levodopa-induced dyskinesias. Ann Neurol 2000;47(suppl 1):S179-S188.
56. 3 receptor function. Nat Med 2003;9(6):762-767.
57. Bézard E, Imbert C, Deloire X, et al. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: evolution of motor symptoms in the monkey. Brain Res 1997;766:107-112.
58. 3 dopamine receptor partial agonist BP897 [N-[4-(2-methoxyphenyl)piperazinyl) butyl]-2-naphthamide] on l-3,4-dihydroxyphenylalanine-induced dyskinesias and parkinsonism in squirrel monkeys. J Pharmacol Exp Ther 2004;311(2):770-777.
59. Johnston TH, Brotchie JM. Drugs in development for Parkinson's disease. Curr Opin Investig Drugs 2004;5(7):720-726.
60. Henry B, Fox SH, Peggs D, et al. The alpha 2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Mov Disord 1999;14(5):744-753.
61. Johnston TH, Lee J, Gomez-Ramirez J, et al. A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Exp Neurol 2005;191(2):243-250.
62. Bloem BR, Irwin I, Buruma OJS, et al. The MPTP model: versatile contributions to the treatment of Parkinson's disease. J Neurol Sci 1990;97:273-293.
63. Jenner P. The contribution of the MPTP-treated primate model to development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 2003;9(3):131-137.
64. Schober A. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 2004;318:215-224.
65. Maratos EC, Jackson MJ, Pearce RK, et al. Both short- and long-acting D-1/D-2 dopamine agonists induce less dyskinesia than levodopa in the MPTP-lesioned common marmoset. Exp Neurol 2003;179(1):90-102.